7:20 AM
May 20, 2019
 |  BC Innovations  |  Distillery Therapeutics

The OXPHOS complex I inhibitor IACS-010759 for mantle cell and B cell lymphoma


INDICATION: Mantle cell lymphoma (MCL); B cell lymphoma

Patient sample, cell culture and mouse studies identified an OXPHOS complex I inhibitor that could help treat MCL and B cell lymphoma that are resistant to Imbruvica ibrutinib. In MCL patients, high expression of genes in multiple OXPHOS complexes, including complex I, was associated with resistance to...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >